Tirzepatide (Mounjaro) in Canada

A GIP and GLP-1 dual agonist, not a semaglutide substitute. Our provider comparison is in editorial testing.

Updated: July 28, 2026

Last reviewed: July 27, 2026 · Editorial team · Canadian availability verified per province

Editorial testing in progress

We have not finished verifying Canadian tirzepatide providers against real provincial availability, and we would rather publish nothing than publish rankings we have not checked. In the meantime, our published categories below are live.

GLP-1 Weight Loss Semaglutide

Prescription notice

GLP-1 medications, finasteride, NAD+ injections and the other treatments compared on this site are prescription-only in Canada. A prescription is issued only when a clinician licensed in your province determines it is clinically appropriate for you. Approval is never guaranteed.

Explore More Treatments

Best GLP-1 Weight Loss in Canada

Health Canada-authorized GLP-1 weight loss programs from licensed Canadian telehealth clinics, compared on all-in monthly cost.

Best Semaglutide in Canada

Semaglutide in Canada — generic, Ozempic and Wegovy — from licensed Canadian telehealth clinics, compared on all-in monthly cost.

Tirzepatide Availability by Province

Telehealth is regulated provincially in Canada. Confirm your province is served before paying a consultation fee.

Ontario British Columbia Alberta Quebec Manitoba Saskatchewan Nova Scotia New Brunswick Prince Edward Island Newfoundland and Labrador

Frequently Asked Questions

No. Semaglutide is a GLP-1 receptor agonist; tirzepatide acts on both the GIP and GLP-1 receptors. They are different molecules with different dosing schedules, and they are not interchangeable. Switching between them is a clinical decision, not a pricing one.

Yes. Health Canada has authorised tirzepatide under the brand name Mounjaro, and it is prescription-only. As with every GLP-1 in Canada, no compounded version is permitted.

References and further reading

Health Canada, Drug Product Database (Health Canada). Whether a specific drug product is authorized for sale in Canada.
Obesity Canada and CMAJ, 2025 pharmacotherapy guideline (CMAJ / Obesity Canada). Canadian obesity guideline on long-term weight-management medicine.

Advertising & Affiliate Disclosure: We may receive compensation when you click on links to partners featured on this site. Our rankings and recommendations are based on our independent research methodology and editorial standards, not on sponsorship or payment. Some links are affiliate links, which means we may earn a commission at no extra cost to you if you make a purchase.

Medical Disclaimer: The content on this site is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for medical questions, treatment decisions, or emergency care. Do not disregard professional medical advice or delay seeking it based on information found here.